Androgen deprivation therapy for prostate cancer: indications, contraindications and possible consequences by Karl, Alexander & Konety, Badrinath
Androgen deprivation therapy for prostate cancer: indications,
contraindications and possible consequences
Alexander Karl* and Badrinath Konety
Address: Department of Urology, School of Medicine, University of California-San Francisco, 1600 Divisadero Street, San Francisco, CA 94143, USA
*Corresponding author: Alexander Karl (karla@urology.ucsf.edu).
F1000 Medicine Reports 2009,1:2 (doi: 10.3410/M1-2)
The electronic version of this article is the complete one and can be found at: http://F1000.com/Reports/Medicine/content/1/2
Abstract
Androgen deprivation therapy (ADT) has been the mainstay of palliative treatment in advanced and
metastatic prostate cancer for many years. It is also increasingly being used in patients with localized
disease. Here we review some recent trials that are providing information on its benefits and
disadvantages in different circumstances.
Introduction and context
In 2008, prostate cancer will be diagnosed in an
estimated 186,320 men in the United States and
approximately 28,660 men will die of the disease,
according to the US National Cancer Institute [1].
Androgen deprivation therapy (ADT) has historically
been the mainstay of treatment in advanced and
metastatic disease. Today ADT is also utilized in patients
with local disease and especially those with high-risk
features undergoing radiation therapy.
Information from the CaPSURE database shows that the
use of primary hormonal therapy for men with localized
prostate cancer has increased significantly among men
with low- and intermediate-risk disease since the 1995
American Urological Association (AUA) guidelines were
published [2]. These data were confirmed by a report
derived from the Surveillance, Epidemiology, and End
Results (SEER)-Medicare database [3].
In general, primary ADT is employed with the goal of
providing symptomatic control of prostate cancer for
patients in whom definitive treatment with surgery or
radiation is not possible or acceptable. The concept of
ADT should be distinguished from the use of neoadju-
vant hormonal therapy (before radical prostatectomy or
radiation therapy) or adjuvant (after radical prostatec-
tomy or radiation therapy) hormonal therapy. The use of
luteinizing hormone-releasing hormone (LHRH) ago-
nists, which downregulate LHRH receptors by interfering
with the hypothalamic-pituitary-gonadal axis, is now
standard in long-term hormonal therapy [4, 5]. Antian-
drogens, in contrast, compete with circulating androgens
for binding receptors. Antiandrogens can be used on
their own (monotherapy), or in combination with
LHRH agonists for combined androgen blockade, or
are used to reduce the risk of a testosterone 'flare' that
often accompanies the initiation of LHRH.
Different modes of androgen deprivation
Bilateral orchiectomy (castration) or subcutaneous
application of LHRH agonists are the predominant
forms of ADT. Goserelin is the most widely studied
LHRH agonist. In patients with locally advanced disease,
goserelin has been shown to significantly improve
overall survival when given as an adjuvant to radio-
therapy [6].
Antiandrogen monotherapy
Non-steroidal antiandrogens are known to affect only
the androgen receptor without presenting direct gonado-
tropic effects. This is part of the explanation of the
maintenance of potency in 70–80% in patients who
receive non-steroidal ADT monotherapy.
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studies of identical design has evaluated whether
monotherapy with the non-steroidal antiandrogen bica-
lutamide might be an alternative to medical or surgical
castration in patients with locally advanced prostate
cancer [7]. In this study, a total of 480 patients with T3-4,
M0 disease were randomized to receive either bicaluta-
mide (150 mg) or castration. After a median follow-up
time of 6.3 years, mortality was 56%, with no significant
difference between bicalutamide and castration in terms
of overall survival (HR 1.05; P = 0.70) or time to
progression (HR 1.20, P = 0.11). Compared with
castration, bicalutamide was better for maintaining
physical activity and libido during the entire treatment
period and afterwards. The data suggest that bicaluta-
mide 150 mg provides a survival outcome similar to that
o b s e r v e dw i t hc a s t r a t i o ni np a t i e n t sw i t hl o c a l l y
advanced disease.
The 2008 European Association of Urology (EAU)
guidelines [8] (Table 1) point out that antiandrogen
monotherapy with bicalutamide is comparable to that
with LHRH agonists in men with minimal tumour
burden. However, the guidelines also state that survival
rates are lower in patients with extensive metastatic
disease, in whom medical or surgical castration should
be favoured.
Complete androgen blockade
On the basis of data from the most recent systematic
reviews and meta-analyses, complete ADT results in a
small median survival benefit (<5%) compared with
monotherapy with LHRH agonists [3, 9]. However,
adverse effects leading to withdrawal of patients from
therapy also occur more often with combined androgen
blockade. Therefore, complete ADT is not recommended
for routine clinical use as a standard therapy [8].
Intermittent androgen blockade
The reasoning behind intermittent androgen blockade is
to reduce treatment-associated side effects, to influence
sensitivity to hormonal treatment and, furthermore, to
lower healthcare costs without compromising therapeu-
tic efficacy. Several phase II trials have demonstrated the
feasibility of intermittent androgen blockade in meta-
static or biochemically recurrent disease, with prostate-
specific antigen (PSA) response rates and symptom
improvement similar to those of complete androgen
blockade.
According to the 2008 EAU Guidelines [8] (Table 1) it is
possible to offer intermittent androgen blockade to
selected patients, but results from randomized trials are
still lacking. A minimum induction period of 7 months
with continuous hormonal therapy and a PSA response
of <4 ng/ml seems to be required for a successful
intermittent regimen.
Recent advances
There are different approaches and aims in using
androgen deprivation. One is the palliation of symptoms
in metastatic cancer and the reduction of risk for
potentially severe sequelae of advanced disease (spinal
cord compression, pathological fractures, ureteral
obstruction and extraskeletal metastasis) [10, 11].
Asymptomatic patients with metastatic disease can also
benefit from immediate androgen deprivation as it could
defer progression to a symptomatic stage and prevent
serious complications related to disease progression [9].
In lymph-node-positive patients, immediate institution
of androgen deprivation has demonstrated prolongation
of progression-free survival. Messing et al. [12] analyzed
the appropriate timing and impact of ADT on survival in
men with node-positive prostate cancer who have
undergone radical prostatectomy and pelvic lymphade-
nectomy compared with those who received ADT at
disease progression. At median follow-up of 11.9 years,
those patients who received immediate ADT had a
significant improvement in overall survival (HR 1.84,
P = 0.04), prostate-cancer-specific survival (HR 4.09,
P = 0.0004), and progression-free survival (HR 3.42,
P < 0.0001).
This study demonstrated that early ADT benefits patients
with nodal metastases who have undergone prostatect-
omy and lymphadenectomy, compared with those who
receive deferred treatment. In his evaluation [13] of this
study, Faculty of 1000 member Adam Kibel poses the
Table 1 The EAU Guidelines [8] give the following
recommendations for hormonal therapy as primary treatment
T1a Not an option (grade A recommendation)
T1b-T2b Symptomatic patients who need palliation of
symptoms and who are unfit for curative treatment
(grade C recommendation)
T3-T4 Symptomatic patients, extensive T3-T4, high PSA
level (>25 ng/ml), unfit patients. Better than watchful
waiting (grade A recommendation)
N+, M0 Standard therapy (grade A recommendation)
M+ Standard therapy. Symptomatic patients should not




To reduce the risk of the flare-up phenomenon in
patients with advanced metastatic disease who are to
receive an luteinising hormone-releasing hormone
agonist (level of evidence: 1b)
Nonsteroidal
antiandrogens
Primary monotherapy as an alternative to castration
in patients with locally advanced PCa (level of
evidence: 1b)
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at the time of prostate-specific antigen (PSA) elevation
would provide the same survival benefit as immediate
androgen deprivation. To our knowledge there is no
study published so far that could give a definite answer
to this question. Further prognostic studies are needed to
evaluate the optimum timing for ADT in detail to reduce
side effects of hormonal therapy as best possible.
The study of Messing et al. [12] is also cited in the 2008
EAU Guidelines on prostate cancer [8]. It is stated that
although the results showed a significant survival
advantage for immediate ADT in lymph-node-positive
patients, it must be acknowledged that most patients had
gross nodal disease and that 70% also had positive
margins and/or seminal vesicle invasion. It is unclear
whether adjuvant androgen deprivation in patients with
minimal nodal involvement would result in the same
positive results.
A recently published Cochrane Database analysis eval-
uated ADT in regard to different primary therapy
approaches [14]. Four studies were included in this
analysis that evaluated adjuvant hormonal therapy
following radiotherapy. There was reported a significant
improvement in overall survival at 5 and 10 years. Also
disease-specific survival and disease-free survival were
statistically improved in favour of adjuvant hormones at
5 years.
According to three evaluated studies, adjuvant hormonal
therapy did not show a statistically significant advantage
in overall survival in patients who underwent primary
radical prostatectomy. However the study of Messing
et al. [12] showed a statistically significant improvement
in disease specific survival at 5 years and 10 years.
Recently, Conti et al. [15] presented a Cochrane database
analysis comparing intermittent ADT and continuous
ADT in prostate cancer patients. Five randomized studies
were included involving a total of 1382 patients. All
patients included were diagnosed with advanced pro-
state cancer (T3 or T4). A subgroup analysis showed no
significant differences in biochemical progression in a
comparison of intermittent and continuous ADT for
patients with Gleason scores 4–6, 7, and 8–10.
No differences between intermittent and continuous
ADT were found in regard to adverse effects – gastro-
intestinal disturbances, gynecomastia (abnormal breast
enlargement) and asthenia. ADT did show a significant
benefit (P = 0.008) in reducing impotence. In their
conclusions the authors state that there are only limited
data on side effects and insufficient data regarding
overall survival, disease-specific survival, or disease
progression in the current literature [10].
Implications for clinical practice
Complications and contraindications
A chosen treatment for prostate cancer can yield benefits,
but it can also harm. As stated above, ADT has shown to
be beneficial and is indicated in different stages of this
disease. On the other hand, ADT can result in a
multitude of endocrine and general complications [16].
Some may affect patients' quality of life, and others
contribute to increased risks for serious health concerns.
Sexual side effects (erectile dysfunction and loss of
libido) are the well recognized adverse effects of ADT.
Eligible patients (see above) could benefit in terms of
erectile dysfunction from non-steroidal antiandrogen
therapy. In an Italian study comparing bicalutamide 150
mg monotherapy with combined androgen block-
ade, significantly fewer patients in the monotherapy
group reported erectile dysfunction (69.2 vs 93.3%,
respectively, P = 0.0002) or loss of libido (59.6 vs
85.5%, respectively, P ≤ 0.01) compared with combined
androgen blockade [16]. There is also evidence that
bicalutamide 150 mg can preserve physical capacity in
comparison with castration [7, 16].
One adverse event that is commonly observed (around
80%) is the incidence of hot flashes, which may not
abate over the course of ADT. Drugs such as estrogens,
progestin megestrol acetate, and venlafaxine have been
shown to decrease hot flashes and associated symptoms
[17].
Loss of bone mineral density associated with castration
can be reduced with biphosphonates, as reported by Aus
et al. [17]. Also, bicalutamide has shown to maintain
bone mineral density [18].
Complications also include recognized physiologic
effects, including gynecomastia and breast pain. Gyne-
comastia and breast pain are the most common adverse
effects associated with treatment of non-steroidal anti-
androgens. In randomized studies, treatment with
tamoxifen has been shown to significantly reduce the
incidence of breast pain and gynecomastia [17]. Ther-
apeutic radiotherapy showed to improve symptoms, but
more effectively for breast pain than for gynecomastia.
Recently, insulin resistance, hyperglycemia, and meta-
bolic syndrome have emerged as metabolic complica-
tions of castration and may be responsible for increased
cardiovascular mortality in this population [18]. Cardio-
vascular disease and diabetes are known to be the
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who survive cancer. It is known that men with prostate
cancer have higher rates of non-cancer mortality than the
general population [19].
A study published by Keating et al. [20] in 2006 analyzed
whether the use of ADT with a LHRH agonist is
associated with an increased incidence of diabetes and
cardiovascular disease. This study observed a cohort of
73,196 patients from the linked database of SEER-
Medicare who were diagnosed with local or loco-
regional prostate cancer in the period 1992–1999. Cox
proportional hazards models were used to assess
whether treatment with LHRH agonists or orchiectomy
was associated with diabetes, coronary heart disease,
myocardial infarction and sudden cardiac death. The
authors report that 36.3% of men received a LHRH
agonist and 6.9% underwent bilateral orchiectomy in
this cohort. After prostate cancer diagnosis, 3,917 men
(5.4%) were diagnosed with myocardial infarction and
3,301 (4.5%) experienced sudden cardiac death. Among
64,721 patients without prevalent diabetes, 10.9%
developed diabetes and among 59,748 without preva-
lent coronary heart disease, 25.3% developed coronary
heart disease. LHRH agonist use was associated with
increased risk of incident diabetes (adjusted HR 1.42,
P < 0.001), coronary heart disease (adjusted HR 1.16,
P < 0.001), myocardial infarction (adjusted HR 1.11,
P = 0.03), and sudden cardiac death (adjusted HR 1.34,
P = 0.004). In contrast, men who underwent orchiect-
omy for ADT were diagnosed more often with diabetes
(HR 1.34, P < 0.001), whereas no significant risk was
detected for coronary heart disease, myocardial infarc-
tion or sudden cardiac death (all P > 0.20).
The authors concluded that LHRH agonist treatment for
men with loco-regional prostate cancer might be
associated with an increased risk of incident diabetes
and cardiovascular disease. Therefore the benefits of
LHRH agonist treatment should be weighed against
these potential risks.
In an evaluation [21] of this paper, Faculty of 1000
member Robert Dreicer states that this important study
of patients with loco-regional prostate cancer treated
with either gonadotropin-releasing hormone (GnRH)
agonists or orchiectomy demonstrated a significant
association of GnRH therapy with diabetes, heart disease
and sudden cardiac death and an association of
orchiectomy with diabetes.
Similar results were presented by Tsai et al. [22], who
analyzed 1,015 patients who received ADT. In their
study, patients older than 65 years who were treated with
ADT in addition to radical prostatectomy had a 5-year
cumulative incidence of cardiovascular death of 5.5%
and those treated with radical prostatectomy alone had a
2.0% incidence of cardiovascular death. Also, younger
patients who were treated with radical prostatectomy
and received ADT were reported with a 5-year cumulative
incidence of cardiovascular death of 3.6% compared
with 1.2% without ADT.
It is therefore important for clinicians to anticipate these
complications and to initiate measures to prevent or
minimize them [22]. Patients who are considered for
ADT should undergo careful cardiovascular evaluation
and receive regular internal check-ups. The risk of ADT
has to be balanced for every patient individually.
Generally, physicians should be aware of the far-reaching
consequences of ADT and should incorporate strategies
for preventing and managing its undesirable side effects
into routine practice. The indications for ADT need to be
assessed more accurately and recommendations for this
therapy restricted more strictly to those categories of
patients that have clearly been shown to benefit from it
in prospective randomized studies.
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